enoblituzumab
mAbexperimental
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators. — Wikipedia
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2011 (NCT01391143)
Timeline
Indications
Studied for
- Carcinoma · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Desmoplastic Small Round Cell Tumor · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hamartoma · Phase 1
- Head and Neck Neoplasms · Phase 2/Phase 3
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Neuroblastoma · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 1
- Sarcoma, Ewing · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2/Phase 3
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Wilms Tumor · Phase 1
Mechanism of action
- CD276 antigenCROSS-LINKING AGENT
CD276 cross-linking agent
- CD276 antigenINHIBITOR
CD276 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnoblituzumab ↗
- ChEMBLCHEMBL3545373 ↗
- ChEMBLCHEMBL2109638 ↗
Also known as
- enoblituzumab
- enoblituzumab
- inc.
- inc.
- macrogenics
- mga271
- mga-271
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06014255 | Phase 2 | Jan 1, 2024 | Johns Hopkins University, MacroGenics |
| NCT05708924 | Phase 1 | Apr 28, 2023 | University of Minnesota |
| NCT04630769 | Phase 1 | Apr 2, 2021 | University of Minnesota |
| NCT04634825 | Phase 2 | Mar 17, 2021 | MacroGenics |
| NCT04129320 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2019 | MacroGenics |
| NCT02982941 | Phase 1 | Dec 1, 2016 | MacroGenics |
| NCT02923180 | Early Phase 1 (Phase 1) | Oct 1, 2016 | Johns Hopkins University |
| NCT02475213 | Phase 1 | Jul 1, 2015 | MacroGenics |
| NCT02381314 | Phase 1 | Mar 1, 2015 | MacroGenics |
| NCT01918930 | Phase 1 | Jul 1, 2013 | Harvard University, MacroGenics |
| NCT01391143 | Phase 1 | Jul 1, 2011 | MacroGenics |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MacroGenics | For profit | 8 | 7 | 3 | 2011 |
| Johns Hopkins University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| University of Minnesota | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1